How Pieces Technologies’ AI is Driving Clinical Efficiency

By Michael Awood

September 14, 2023

Significant progress is being made in healthcare by Pieces Technologies Inc.

Healthcare professionals use its Artificial Intelligence (AI) platform to manage cases, plan discharges, and reduce hospital stays. Recently, the AI wrote its one-millionth clinical summary – in just seven months. This displays the role and impact that AI can have in healthcare.

The Pieces system uses advanced technology and human help to ensure high accuracy while maintaining a hallucination rate of less than 0.1%. “Hallucinations” refer to instances where the AI produces incorrect or nonsensical outputs. However, Pieces shows great promise in this area with a considerable improvement compared to existing models. This high accuracy is further evidenced by the reduced need for edits in the system’s output.

The software is a trusted tool for healthcare professionals, supporting various clinical procedures and contributing to efforts aimed at reducing patient stay duration and readmission rates.
This achievement highlights the potential of applied clinical generative AI in healthcare delivery. Pieces Technologies has committed to safety, transparency, and accountability to improve healthcare outcomes and operations.

Pieces Technologies is leading the way in redefining healthcare through AI, achieving clinical efficiency and patient care. The system is set to be implemented in pediatric hospital environments soon, further expanding its impact. This highlights the importance of AI in healthcare, not to surpass benchmarks, but to enhance patient care and clinical outcomes.

 

Cover image source: PR Newswire. Link in the reference URL

Reference url

Recent Posts

PIONEER TEENS Trial Reveals Oral Semaglutide Diabetes Breakthrough for Pediatric Patients

By João L. Carapinha

April 24, 2026

Important results from the PIONEER TEENS phase 3a trial! Oral semaglutide diabetes therapy delivered statistically superior glycemic control compared with placebo in children and adolescents aged 10–17 years with type 2 diabetes. The trial met its primary endpoint with a 0.83% greater reduction i...
Advancing Multicenter AKI Prediction: Benefits of Collaborative Models Over Localized Approaches
New evidence demonstrates that multicenter AKI prediction models significantly outperform locally trained single-center models for forecasting postoperative acute kidney injury (AKI) after cardiac surgery. The study, published in npj Digital Medicine, analyzed 43,926 cardiac surgery c...
Advancements in Rare Disease Therapies: CHMP’s April 2026 Insights and Economic Implications
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommendations from its 20–23 April 2026 meeting, included a particular focus on rare disease therapies. The CHMP issued positive opinions for five new medicines, three of which carry orphan designation, alo...